XLV vs IBB Stock Comparison: AI Score, Valuation, Performance and Upside
XLV and IBB both provide healthcare sector exposure, but at very different levels of focus and volatility. XLV is a diversified healthcare sector fund covering pharma, managed care, devices, and biotech with defensive characteristics; IBB is a concentrated biotech-only fund more sensitive to clinical trial outcomes, M&A, and the innovation cycle. XLV is appropriate for defensive healthcare allocation; IBB is for investors making a specific bet on biotech.
XLV vs IBB is a choice between defensive broad healthcare diversification and concentrated biotech innovation exposure — XLV provides recession resilience and lower volatility, while IBB provides higher return potential in biotech bull cycles at significantly higher cost and risk.
XLV holds the edge across 4 of 5 key metrics in this comparison. IBB has delivered stronger 1-year price return (+38.41% vs +14.13% for XLV).
- →prefer broad defensive healthcare sector exposure across pharma, managed care, devices, and biotech
- →value the very low 0.09% expense ratio for efficient healthcare sector allocation
- →want recession-resistant equity exposure from inelastic medical demand across all healthcare subsectors
- →are comfortable with managed care and drug pricing regulatory risk as the primary policy headwinds
- →prefer pure-play biotech sector exposure to capture FDA approvals, clinical trial breakthroughs, and M&A premiums
- →value broad biotech coverage (250+ names) including small-cap pipeline companies alongside large commercial biotechs
- →want exposure to the biotechnology innovation cycle specifically, without pharmaceutical or managed care dilution
- →are comfortable paying 0.45% expense ratio and accepting higher volatility for concentrated biotech sector exposure
| Metric | XLV | IBB |
|---|---|---|
| ETF score | 58.0 | 48.0 |
| Latest close | $149.40 | $173.64 |
| 1M return | +1.41% | +5.77% |
| 6M return | -2.04% | +3.74% |
| 1Y return | +14.13% | +38.41% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | XLV | IBB |
|---|---|---|
| 1Y ago | $11.62K (+16.2%) started 2025-06-18 | $13.88K (+38.8%) started 2025-06-18 |
| 5Y ago | $14.22K (+42.2%) started 2021-06-18 | $11.23K (+12.3%) started 2021-06-18 |
| 10Y ago | $29.77K (+197.7%) started 2016-06-20 | $21.23K (+112.3%) started 2016-06-20 |
Hypothetical — past performance does not guarantee future results.
| Metric | XLV | IBB |
|---|---|---|
| Expense ratio | 0.08% | 0.44% |
| Total assets (AUM) | $38.25B | $7.94B |
| Dividend yield | 1.68% | 0.23% |
| Trailing P/E | 24.10 | 22.48 |
| Beta | 0.58 | 0.72 |
| 52-week change | 14.13% | 38.41% |
| Metric | XLV | IBB |
|---|---|---|
| 1Y return | +14.13% | +38.41% |
| 6M return | -2.04% | +3.74% |
| 1M return | +1.41% | +5.77% |
| 1Y Sharpe ratio | 0.66 | 1.49 |
| Beta | 0.58 | 0.72 |
| Dividend yield | 1.68% | 0.23% |
| 5Y CAGR | +5.53% | +2.08% |
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | XLV | IBB |
|---|---|---|---|
| 1Y | Growth | +14.13% | +38.41% |
| CAGR | +14.14% | +38.44% | |
| Sharpe ratio | 0.66 | 1.49 | |
| Max drawdown | 10.47% | 9.63% | |
| Max daily drop | 2.80% | 3.01% | |
| Max wkly drop | 4.68% | 5.15% | |
| 5Y | Growth | +30.86% | +10.82% |
| CAGR | +5.53% | +2.08% | |
| Sharpe ratio | 0.13 | -0.00 | |
| Max drawdown | 17.11% | 39.82% | |
| Max daily drop | 5.48% | 5.77% | |
| Max wkly drop | 8.36% | 12.64% | |
| 10Y | Growth | +149.43% | +106.74% |
| CAGR | +9.58% | +7.54% | |
| Sharpe ratio | 0.36 | 0.24 | |
| Max drawdown | 28.40% | 39.82% | |
| Max daily drop | 9.86% | 8.96% | |
| Max wkly drop | 13.20% | 18.45% |
| Category | XLV | IBB |
|---|---|---|
| Fund name | State Street Health Care Select Sector SPDR ETF | iShares Biotechnology ETF |
| Type | ETF | ETF |
| Expense ratio | 0.08% | 0.44% |
| Total assets (AUM) | $38.25B | $7.94B |
| Dividend yield | 1.68% | 0.23% |
- →Broadest healthcare sector coverage (pharma, managed care, devices, biotech, services) reduces single-subsector concentration risk
- →0.09% expense ratio is one of the lowest sector ETF fees, minimizing cost drag
- →Defensive healthcare sector typically outperforms in recessions and market downturns due to inelastic medical demand
- →Pure biotech exposure means IBB captures the full innovation cycle from small-cap pipeline to large-cap commercial biotechs
- →250+ holdings provides broad biotech diversification versus speculative single-stock biotech positions
- →Large-cap commercial biotech holdings (Amgen, Gilead, Vertex) provide revenue stability alongside pipeline optionality
- →Drug pricing regulation and Medicare negotiation policy create legislative risk that can depress pharma stock valuations
- →Managed care companies face medical cost ratio pressure, and ACA/Medicaid policy uncertainty creates regulatory headwinds
- →Biotech trial failures in large XLV holdings (e.g., AbbVie, Regeneron) can impact the fund meaningfully
- →0.45% expense ratio is 5x more expensive than XLV's 0.09%
- →Biotech-only focus creates more volatility than XLV's diversified healthcare exposure
- →IBB has no managed care, device, or pharma exposure — significant parts of the healthcare sector returns are missed
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.